Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
General Montana
Archived
•
October 8, 2026
•
SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED)
Source: Missoulian MT | https://missoulian.com/search/?f=rss&t=article&l=50&s=start_time&sd=desc - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



